AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed advanced solid tumors or lymphoma
* Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field
* Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator
* No untreated or symptomatic brain metastases
* No tumors with direct bowel invasion
* No other hematological malignancies
* No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum)

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Not pregnant
* No nursing during and for 6 months after completion of study treatment
* Fertile patients must use effective contraception during and for 6 months after completion of study treatment
* Negative pregnancy test
* Able to swallow oral medication
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9 g/dL
* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min
* Albumin-adjusted calcium ≥ 8 mg/dL
* Urine protein \< 30 mg/dL by urinalysis or \< 1+ by dipstick OR \< 500 mg by 24-hour urine collection
* AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm)
* Bilirubin ≤ 2 times ULN
* PT ≤ 2.0
* INR or PTT ≤ 1.5 times ULN
* Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed)
* No myocardial infraction within the past year
* No arterial thrombosis or deep vein thrombosis within the past year
* No unstable angina
* No congestive heart failure
* No New York Heart Association class III-IV cardiac disease
* No other unstable or uncontrolled disease or condition relating to or impacting cardiac function
* No HIV positivity
* No other condition that would preclude study participation, compliance, or follow-up assessments

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior enrollment into this study
* At least 1 month since prior investigational device or drug trial
* At least 1 month since prior major surgical procedure
* At least 3 weeks since prior systemic chemotherapy
* At least 2 weeks since prior radiotherapy
* At least 2 weeks since prior rifampin or phenobarbital
* At least 1 week since prior treatment with any of the following:

  * Ketoconazole
  * Itraconazole
  * Clarithromycin
  * Erythromycin
  * Cyclosporine or tacrolimus
  * Nefazodone
  * Herbal medications containing Hypericum perforatum (St. John's wort)
* At least 1 week since prior and no concurrent warfarin

  * Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin \[≤ 2 mg/day\] or low molecular weight heparin) for venous or arterial access devices allowed
* No prior or concurrent kinase insert domain-receptor inhibitors
* No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy

  * Gonadotropin releasing-hormone agonist therapy allowed
* No concurrent interferon
* No concurrent grapefruit juice or whole grapefruit
* No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors
* No elective surgery during or for 2 weeks after completion of the last dose of AMG 706